Acquisition | MORPHOSYS AG | 10th June 2024

On April 11, 2024, NOVARTIS AG launched a tender offer to acquire entire share capital of MORPHOSYS AG. Each shareholder of MORPHOSYS AG will receive EUR 68 in cash for every share held. Considering each MORPHOSYS ADS represent 0.25 share, each ADS holder will receive EUR 17 for every DR held. The additional acceptance period of the tender offer expired on May 30,2024. Based on the announcement made on June 4, 2024, NOVARTIS AG holds 89.47 percent of share capital of MORPHOSYS AG. Since the free float has dropped below 15 percent, Solactive AG will remove MORPHOSYS AG giving 2 days notice.

The treatment below will be applied to the following indices:

• MORPHOSYS AG will be removed from the Index.
• The weight of MORPHOSYS AG (MOR.OQ) based on its last close price will be distributed pro rata to remaining Index constituents.
• Effective Date (open): 10/06/2024

Solactive United States Biotechnology Index NTR
Solactive United States Biotechnology Index PR
Solactive United States Biotechnology Index TR